ARQT

24.58

2.03% -0.51

시간 외 거래: 24.28 -0.30 -1.22%

Arcutis Biotherapeutics Inc (ARQT)

개요 뉴스 가격 이력 옵션 체인 Financials ARQT 왜 하락? 토론 예측

전일 마감가:

$25.09

열려 있는:

$25.09

하루 거래량:

775.36K

Relative Volume:

0.58

시가총액:

$3.05B

수익:

$376.07M

순이익/손실:

$-16.14M

주가수익비율:

-175.70

EPS:

-0.1399

순현금흐름:

$-16.31M

1주 성능:

-0.12%

1개월 성능:

+8.04%

6개월 성능:

+13.64%

1년 성능:

+86.35%

1일 변동 폭

$24.21

$25.33

1주일 범위

$23.59

$25.47

52주 변동 폭

$12.42

$31.77

Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile

명칭

Arcutis Biotherapeutics Inc

부문

Healthcare (1112)

산업

Biotechnology (621)

전화

805-418-5006

주소

3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA

직원

354

트위터

@ArcutisBio

다음 수익 날짜

2024-12-06

최신 SEC 제출 서류

ARQT's Discussions on Twitter

Compare ARQT vs VRTX, REGN, ARGX, ALNY, ONC

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
ARQT Arcutis Biotherapeutics Inc	24.58	3.11B	376.07M	-16.14M	-16.31M	-0.1399
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2025-07-25	개시	Goldman	Neutral
2024-12-30	개시	H.C. Wainwright	Buy
2024-08-28	개시	Jefferies	Buy
2024-01-03	업그레이드	Mizuho	Neutral → Buy
2023-10-26	다운그레이드	Mizuho	Buy → Neutral
2023-10-13	다운그레이드	Goldman	Buy → Neutral
2022-09-07	개시	Needham	Buy
2022-03-17	개시	Goldman	Buy
2021-06-30	개시	Mizuho	Buy
2021-05-27	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2020-11-09	업그레이드	Goldman	Neutral → Buy
2020-10-08	개시	Truist	Buy
2020-02-25	개시	Cantor Fitzgerald	Overweight
2020-02-25	개시	Cowen	Outperform
2020-02-25	개시	Goldman	Neutral
2020-02-25	개시	Guggenheim	Buy

모두보기

Arcutis Biotherapeutics Inc 주식(ARQT)의 최신 뉴스

04:19 AM

Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026 - The Manila Times

04:19 AM

04:00 AM

Arcutis to give business update with Q1 results after market close May 6 - Stock Titan

04:00 AM

07:27 AM

Needham Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $36 - Moomoo

07:27 AM

12:08 PM

Arcutis Biotherapeutics (ARQT) price target increased by 10.24% to 35.70 - MSN

12:08 PM

Apr 14, 2026

Arcutis Biotherapeutics Targets ZORYVE Expansion, Raises 2026 Outlook and Turns Cash-Flow Positive - Yahoo Finance

Apr 14, 2026

Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Emerges as a High-Growth Momentum Breakout Candidate - ChartMill

Apr 14, 2026

(ARQT) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Apr 14, 2026

Apr 13, 2026

Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35 - Moomoo

Apr 13, 2026

Apr 11, 2026

Arcutis (ARQT) announces long-term phase 3 data for ZORYVE cream in children - MSN

Apr 11, 2026

Apr 08, 2026

Is It Too Late To Revisit Arcutis Biotherapeutics (ARQT) After A 75% One-Year Surge? - Yahoo Finance

Apr 08, 2026

Arcutis Stock Up 65% as Director Sells 10,000 Shares Under 10b5-1 Plan. Here's What Investors Should Know - The Globe and Mail

Apr 08, 2026

Arcutis Stock Up 65% as Director Sells 10,000 Shares Under 10b5-1 Plan. Here's What Investors Should Know - The Motley Fool

Apr 08, 2026

How The Arcutis Biotherapeutics (ARQT) Story Is Evolving As Analysts Cluster Around US$35 Targets - Yahoo Finance

Apr 08, 2026

Apr 07, 2026

Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales - Bitget

Apr 07, 2026

Aberdeen Group plc Sells 88,637 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat

Apr 07, 2026

Apr 04, 2026

Perpetual Ltd Sells 1,113,976 Shares of Arcutis Biotherapeutics, Inc. $ARQT - marketbeat.com

Apr 04, 2026

Apr 03, 2026

Insider Sell: Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics Inc (ARQT) - GuruFocus

Apr 03, 2026

Insider Selling: Arcutis Biotherapeutics (NASDAQ:ARQT) Director Sells 10,000 Shares of Stock - marketbeat.com

Apr 03, 2026

Insider sales reported at Arcutis Biotherapeutics (NASDAQ: ARQT) — two 10,000-share disposals - Stock Titan

Apr 01, 2026

Analysts Are Optimistic We'll See A Profit From Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Moomoo

Apr 01, 2026

Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference - The Manila Times

Apr 01, 2026

Mar 31, 2026

Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 8.7%Here's Why - MarketBeat

Mar 31, 2026

Zevenbergen Capital Investments LLC Acquires Shares of 418,035 Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat

Mar 31, 2026

Arcutis executives join Needham virtual health conference April 14 - Stock Titan

Mar 31, 2026

Mar 30, 2026

Tudor Investment Corp ET AL Invests $1.32 Million in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat

Mar 30, 2026

Mar 29, 2026

Aug Big Picture: What are the future prospects of Arcutis Biotherapeutics Inc2026 Institutional & High Accuracy Trade Signal Alerts - baoquankhu1.vn

Mar 29, 2026

Mar 28, 2026

Arcutis presents trial data on roflumilast cream for infants By Investing.com - Investing.com Canada

Mar 28, 2026

Arcutis presents trial data on roflumilast cream for infants - Investing.com

Mar 28, 2026

Arcutis Biotherapeutics Reports Positive Phase 2 Trial Results for ZORYVE® Cream in Infants with Atopic Dermatitis - Quiver Quantitative

Mar 28, 2026

Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting - The Manila Times

Mar 28, 2026

Nearly half of infants saw eczema itch ease in 10 minutes - Stock Titan

Mar 28, 2026

Mar 27, 2026

Nordea Investment Management AB Acquires New Holdings in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat

Mar 27, 2026

Mar 26, 2026

[SCHEDULE 13G/A] Arcutis Biotherapeutics, Inc. Amended Passive Investment Disclosure - Stock Titan

Mar 26, 2026

Silverleafe Capital Partners LLC Increases Stock Holdings in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat

Mar 26, 2026

Mar 23, 2026

Understanding the Setup: (ARQT) and Scalable Risk - Stock Traders Daily

Mar 23, 2026

Arcutis Biotherapeutics (ARQT) Valuation Check After New Pediatric ZORYVE Phase 3 Extension Data - Yahoo Finance

Mar 23, 2026

Mar 19, 2026

A Look At Arcutis Biotherapeutics (ARQT) Valuation After Recent Share Price Weakness - simplywall.st

Mar 19, 2026

Mar 18, 2026

Arcutis (ARQT) Announces Long-Term Phase 3 Data for ZORYVE Cream in Children - Insider Monkey

Mar 18, 2026

Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting - Bitget

Mar 18, 2026

Arcutis Biotherapeutics (ARQT) Unveils New Trial Data at Dermato - GuruFocus

Mar 18, 2026

New eczema treatment data in infants and kids set for 2026 AAD - Stock Titan

Mar 18, 2026